Ann: EMVision Commences Clinical Trial, page-26

Hi Kogarahboy,

You have known me long enough now on HC to know that drops in SP in stocks I have conviction in don’t bother me. EMV is very illiquid and moves fast both ways and on minimal volume.

BTW, these are not the first real patients we have scanned and we have already proven the device to show both Ischemic and Hemorrhagic strokes in 50 patients in the PAH pilot study. Now it’s just about repeating results and perhaps improving the accuracy of how we can localise and differentiate stroke types with more data sets. AI and machine learning.

EMV will update the market when it Is prudent to do so and I have full faith in the team’s communications, as has been proven time and time again. If there was anything seriously wrong we would know by now.

From where I sit it’s all going well and we just need to be patient. The SP action on this stock for various reasons is often not linked to the actual business but sentiment driven in any quieter time. And we know how unprofitable tech stocks have been doing lately in the broader market.

Just my two cents worth but I am more than comfortable with my holding and will add on any significant weakness. IMO these shares will be collectors items over the next 12 to 18 months.

We are in as good hands as we could be from a management team perspective.

DYOR and Not advice.